Fluorouracil Clinical Trials
65 recruitingDrug
Phase 232Phase 123Phase 318Phase 41Not Applicable1
Showing 1–20 of 65 trials
Recruiting
Phase 3
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
Biliary Tract Cancer
Sichuan Baili Pharmaceutical Co., Ltd.398 enrolled2 locationsNCT07606599
Recruiting
Phase 3
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)
Biliary Tract Cancer
Sichuan Baili Pharmaceutical Co., Ltd.538 enrolled1 locationNCT07582315
Recruiting
Phase 3
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Metastatic Colorectal CarcinomaStage IV Colorectal Cancer AJCC v8Unresectable Colorectal Carcinoma+1 more
ECOG-ACRIN Cancer Research Group408 enrolled60 locationsNCT05863195
Recruiting
Phase 1
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
Gastroesophageal Junction AdenocarcinomaClinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8+10 more
M.D. Anderson Cancer Center24 enrolled1 locationNCT04615013
Recruiting
Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled483 locationsNCT05564377
Recruiting
Phase 1
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Advanced Solid Tumors
Astellas Pharma Global Development, Inc.798 enrolled15 locationsNCT05719558
Recruiting
Phase 2
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Stage I Bladder Cancer AJCC v8Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
National Cancer Institute (NCI)160 enrolled134 locationsNCT06770582
Recruiting
Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Malignant Uterine NeoplasmPeritoneal CarcinomatosisClinical Stage IV Gastric Cancer AJCC v8+24 more
City of Hope Medical Center49 enrolled3 locationsNCT04329494
Recruiting
Phase 1
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Triple-Negative Breast CancerColorectal, CancerAdvanced Breast Cancer+2 more
Pfizer260 enrolled13 locationsNCT07318805
Recruiting
Phase 1
A Study of ASP3082 in Adults With Advanced Solid Tumors
Solid Tumor
Astellas Pharma Inc681 enrolled62 locationsNCT05382559
Recruiting
Phase 2Phase 3
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
Metastatic Pancreatic Ductal AdenocarcinomaPDAC
AbbVie900 enrolled19 locationsNCT07490301
Recruiting
Phase 1
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Gastric AdenocarcinomaPancreatic AdenocarcinomaGastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.398 enrolled46 locationsNCT05365581
Recruiting
Phase 2
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
AbbVie390 enrolled56 locationsNCT06820463
Recruiting
Phase 2
Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
Peritoneal CarcinomatosisMetastatic Gastric AdenocarcinomaMetastatic Gastroesophageal Junction Adenocarcinoma
Sixth Affiliated Hospital, Sun Yat-sen University79 enrolled1 locationNCT04840264
Recruiting
Phase 1
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
Stage IV Colorectal Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Metastatic Colorectal Adenocarcinoma+1 more
National Cancer Institute (NCI)24 enrolled13 locationsNCT06696768
Recruiting
Phase 1Phase 2
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
Advanced or Metastatic Colorectal Cancer
Janssen Research & Development, LLC225 enrolled53 locationsNCT05379595
Recruiting
Phase 3
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+12 more
Alliance for Clinical Trials in Oncology382 enrolled794 locationsNCT05677490
Recruiting
Phase 2
Pan Tumor Rollover Study
Cancer
Bristol-Myers Squibb1,500 enrolled399 locationsNCT03899155
Recruiting
Not Applicable
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Esophageal CarcinomaGastric CarcinomaGastroesophageal Junction Carcinoma+7 more
Alliance for Clinical Trials in Oncology420 enrolled344 locationsNCT07283939
Recruiting
Phase 3
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Urinary Bladder NeoplasmsUrothelial Cancer
Astellas Pharma Global Development, Inc.390 enrolled11 locationsNCT07566156